Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07183319 · ClinicalTrials.gov registry record · Phase 2

Circulating Tumor DNA Response In Urothelial Cancer

A Phase 2 study of Urothelial Carcinoma, sponsored by University of Oklahoma.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT07183319: Recruiting Phase 2 study of Urothelial Carcinoma, sponsored by University of Oklahoma.

NCT07183319 is a Phase 2 study of Urothelial Carcinoma that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 30 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07183319, a Phase 2 study of Urothelial Carcinoma, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).

Primary Outcome

Number of patients who achieve PFS at the 3-month mark on pembrolizumab monotherapy. These patients will undergo radiographic assessments to evaluate progression-free survival (PFS).

Conditions Studied

Urothelial Carcinoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Pembrolizumab & Enfortumab Vedotin (PEV)

Study Locations (1)

Oklahoma

  • OU Health Stephenson Cancer Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-01-19
Est. Completion 2029-03
Phase Phase 2
University of Oklahoma

358 total trials

What NCT07183319 shows while recruiting

NCT07183319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT07183319 reports a single indexed study location in Oklahoma.

Frequently Asked Questions

What is clinical trial NCT07183319 about?

NCT07183319 is a clinical study titled "Circulating Tumor DNA Response In Urothelial Cancer". The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).

What is the current status of trial NCT07183319?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-01-19. Estimated completion is 2029-03.

What conditions does trial NCT07183319 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

What interventions are being tested in trial NCT07183319?

The interventions under investigation include: Pembrolizumab (DRUG), Pembrolizumab & Enfortumab Vedotin (PEV) (DRUG).

Who is sponsoring clinical trial NCT07183319?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07183319 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07183319's enrollment target sits among peer trials

30 64th of 85 higher than 21 of 85 other Urothelial Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07183319

Source: ClinicalTrials.gov NCT07183319, the US trial registry maintained by the National Library of Medicine. NCT07183319 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.